LAB vs LMT · rev $174.4M vs P/E 20, rev $75.05B
Standard Biotools Inc (LAB) versus Lockheed Martin Corporation (LMT) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Lockheed Martin Corporation (LMT) is a aerospace & defense company listed on US. It is led by Jim Taiclet.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported LMT revenue for 2025-12-31 was $75.05B. Net income was $5.02B. Revenue was up 5.6% from 2024-12-31 to 2025-12-31. LMT currently screens at market cap $108.37B and trailing P/E 19.9.
LAB currently screens at market cap $317.1M. LMT currently screens at market cap $108.37B and trailing P/E 19.9.
Not investment advice. Open the LAB and LMT stock pages for the full models.
Not investment advice.